U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07515820) titled 'SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study' on March 30.
Brief Summary: To evaluate the safety and efficacy of SHR-3821 combined with fruquintinib in the advanced colorectal cancer after failure of standard therapy
Study Start Date: April 27
Study Type: INTERVENTIONAL
Condition:
Colorectal Cancer
Intervention:
DRUG: SHR-3821 and fruquintinib
SHR-3821, administered by intravenous infusion Fruquintinib, administered orally
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Meng Qiu
Information provided by (Responsible Party): Meng Qiu, West China Hospital
Disclaimer: Curated by HT Syndication....